Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
https://www.fool.com/investing/2024/07/04/mounjaro-and-zepbound-are-great-but-this-is-the-re/?source=iedfolrf0000001
Jul 04, 2024 - Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.
0
Wall Street firm gets it right with Best Buy call, plus Eli Lilly shares move up
https://www.cnbc.com/2024/07/03/street-gets-it-right-with-best-buy-call-plus-eli-lilly-shares-move-up.html
Jul 03, 2024 - The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
0
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimer-s-drug-donanemab?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296481
Jul 03, 2024 - Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
0
Eli Lilly wins FDA approval of donanemab for Alzheimer's
https://seekingalpha.com/news/4121800-eli-lilly-wins-fda-approval-donanemab-alzheimers?source=feed_sector_healthcare
Jul 02, 2024 - The FDA approves Eli Lilly's Kisunla for early Alzheimer's treatment, costing $32,000 per year.
0
This Is Massive News for Eli Lilly Investors
https://www.fool.com/investing/2024/06/29/this-is-massive-news-for-eli-lilly-investors/?source=iedfolrf0000001
Jun 29, 2024 - A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
0
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
https://www.fool.com/investing/2024/06/29/eli-lilly-is-teaming-up-with-openai-here-are-3-thi/?source=iedfolrf0000001
Jun 29, 2024 - Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector.
0
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
https://seekingalpha.com/news/4119106-resmed-cut-at-oppenheimer-after-eli-lillys-tirzepatide-sleep-apnea-data?source=feed_sector_healthcare
Jun 25, 2024 - ResMed (RMD) stock downgraded at Oppenheimer due to potential impact of Eli Lilly's weight loss therapy tirzepatide on obstructive sleep apnea. Read more here.
0
Eli Lilly collaborates with OpenAI for medicines against drug-resistant bacteria
https://seekingalpha.com/news/4119028-eli-lilly-collaborates-with-openai-for-medicines-against-drug-resistant-bacteria?source=feed_sector_healthcare
Jun 25, 2024 - Eli Lilly partners with OpenAI to develop new antimicrobials using generative AI, advancing drug research against drug-resistant pathogens.
0
ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug
https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound?source=feed_sector_healthcare
Jun 22, 2024 - ResMed (RMD) and Philips (PHG) stocks fall as Eli Lilly's (LLY) seeks a potential label expansion for tirzepatide in obstructive sleep apnea this year. Read more here.
0
Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
https://www.cnbc.com/2024/06/21/eli-lilly-expects-fda-decision-on-zepbound-for-sleep-apnea-as-early-as-end-of-year.html
Jun 21, 2024 - Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved "disease resolution" in the two trials.
0